Disclosed herein are compositions comprising a GLP-1R agonist composition, a DPP-4 inhibitor composition, or a combination of both. The description contained herein describes methods for inducing weight loss and/or boosting satiety in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
Disclosed herein are compositions comprising a GLP-1R agonist composition, a DPP-4 inhibitor composition, or a combination of both. The description contained herein describes methods for inducing weight loss and/or boosting satiety in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.
Disclosed herein are compositions comprising one or more polyglutamic acid compounds. The compositions are for treating, ameliorating, preventing, or reducing the symptoms of vaginal dryness and the symptoms associated with menopause. Also described herein are suppository formulations of the compositions.
Disclosed herein are compositions for treating, ameliorating, preventing, or reducing the symptoms associated with menopause and/or hot flashes. The compositions disclosed herein comprise a curcumin composition, a green tea extract composition, and a phycocyanin composition that act as neurokinin 3 receptor antagonists. Also described herein are methods utilizing the aforementioned compositions.
Compositions comprising lactoferrin are described herein, which can allow for the use of ingredients in a formulation that previously could not be used, or combined together without encountering stability problems. The lactoferrin can also be included so as to eliminate the need for capsule-in-capsule formulations or embodiments comprising lactoferrin and a probiotic. As described herein, certain embodiments of the disclosure can comprise an active ingredient. An active ingredient can comprise one or more of a probiotic formulation, nutritional supplement, and a foodstuff. In certain embodiments, a probiotic formulation, nutritional supplement, and/or foodstuff. In certain embodiments, an active ingredient is a high water activity ingredient.
Processes for producing oligo-chromopeptides from phycocyanin are disclosed. Additionally, compositions comprising oligo-chromopeptides and combination of oligo-chromopeptides with at least one of the compounds namely, nicotinamide riboside, zinc, selenium, or a combination thereof are disclosed. Uses and methods of treating, preventing, or ameliorating age-related somatic disease, bacterial and/or viral infections/diseases, and diseases associated with oxidative stress, or symptoms associated with any of the foregoing are also disclosed.
The present application relates to compositions and salts which may be useful for mediating NO production and improving L-arginine bioavailability in a subject. Methods of using the compositions and salts are also provided.
The present application relates to the treatment of autoimmune disorders, such as CIS or RRMS using biotin compositions. The present application also relates to the delay of progression from CIS to RRMS and RRMS to PPMS using biotin compositions. Also disclosed are methods of reducing pro-inflammatory cytokines using biotin compositions.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present application relates to the treatment of autism and autism spectrum disorders using biotin compositions. In some embodiments, a biotin salt can be used to treat an autism spectrum disorder. In some embodiments magnesium biotinate can be used to treat an autism spectrum disorder.
The present application is directed to composition comprising various maca extracts and the use of such compositions for treating certain diseases, disorders, and conditions.
The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.
The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.
The present disclosure relates to the use of inositol-stabilized arginine ("ASI") for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Some embodiments include the use of ASI for improving mental focus and/or attention span. For example, in some implementations, methods include administering an amount of ASI effective to improve mental focus and/or attention span in humans. Some embodiments include the use of ASI for treating and/or preventing cognitive disorders. Cognitive disorders may include stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss, attention deficit hyperactivity disorder ("ADHD"), and other learning disabilities.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
14.
CHROMIUM HISTIDINATE AND CHROMIUM PICOLINATE COMPLEXES
This present disclosure generally relates to the discovery that chromium histidinate (CrHis) and chromium picolinate (CrPic) can exist as complexes in multiple forms. More particularly, the present disclosure is directed to the surprising discovery that particular forms/isomers (or combinations of forms/isomers) of such chromium complexes have greater activity than others.
A composition comprising chromium and insulin and/or a chromium-insulin complex, its method of preparation, and its use in the prevention and treatment of hypoglycemia and hypoglycemia-related conditions. This composition can be administered in numerous ways, including parenterally, intranasally, and orally. The composition stabilizes serum glucose levels and has a synergistic effect compared to chromium and insulin administered separately.
brevets
